2-Methoxyjuglone
2-Methoxyjuglone, a naphthoquinone, is an apoptosis inducer. 2-Methoxyjuglone activates caspase-9 and caspase-3 via the mitochondrial cytochrome c-dependent intrinsic apoptosis cascade. 2-Methoxyjuglone increases pro-apoptotic Bax levels, decreases anti-apoptotic Bcl-2 levels, and promotes mitochondrial cytochrome c release. 2-Methoxyjuglone induces apoptosis morphological features, early apoptosis, S-phase and G2/M-phase cell cycle arrest, and DNA double-strand breaks. 2-Methoxyjuglone exerts activity against Gram-positive bacteria, pathogenic fungi, and phytopathogenic fungi. 2-Methoxyjuglone can be used for the research of hepatocellular carcinoma, osteosarcoma, colon adenocarcinoma, breast cancer, fungal infection, bacterial infection.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 15127-94-3
- Formule: C11H8O4
- Masse moléculaire:204.18
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Voir tous les produits spécifiques à Isoform Caspase
MoreVoir tous les produits spécifiques à Isoform DNA/RNA Synthesis
More
Activité biologique
|
Caspase 3 |
Caspase 9 |
Bax |
Bcl-2 |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
0.08 μg/mL
Compound: 4
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
[PMID: 9599266] |
2-Methoxyjuglone (1.6-8.0 μg/mL; 24, 48, 72 h) reduces HepG2 human hepatocellular carcinoma cell viability in a dose- and time-dependent manner, with IC50 values of 3.8, 3.7, and 2.7 μg/mL after 24, 48, and 72 h of treatment, respectively[1].
2-Methoxyjuglone (4.8-8.0 μg/mL; 24 h) induces apoptotic morphological changes (cell shrinkage, membrane blebbing) in HepG2 human hepatocellular carcinoma cells[1].
2-Methoxyjuglone (1.6-8.0 μg/mL; 24, 48 h) induces S phase cell cycle arrest in HepG2 human hepatocellular carcinoma cells after 24 and 48 h of treatment at 1.6-8.0 μg/mL, and causes DNA fragmentation (sub-G1 phase accumulation) at 6.4 and 8.0 μg/mL after 48 h[1].
2-Methoxyjuglone (1.6-4.8 μg/mL; 24 h) induces HepG2 human hepatocellular carcinoma cell apoptosis via the mitochondrial cytochrome c-dependent intrinsic pathway, with dose-dependent increases in cytochrome c release, caspase-9 and caspase-3 activation, PARP cleavage, and Bax/Bcl-2 ratio after 24 h of treatment at 1.6-4.8 μg/mL[1].
2-Methoxyjuglone (10 μM; 1.25 μM, 24 h) potently inhibits DNA topoisomerase II at 10 μM and induces DNA double-strand breaks in human osteosarcoma U2OS cells at 1.25 μM, contributing to its cytotoxic activity[2].
2-Methoxyjuglone (62.5 μg/mL; 100 μM) exhibits potent in vitro antibacterial activity against multiple Gram-positive bacterial strains, with 100% growth inhibition of Bacillus subtilis at 100 μM, strong activity against Bacillus subtilis at 62.5 μg/mL[2].
2-Methoxyjuglone (0.25%-4%; 250 μg/mL; 8 μg/mL; 0.1-0.5 mg/mL) exhibits broad-spectrum in vitro antifungal activity against pathogenic and phytopathogenic fungi, with 100% inhibition of Fusarium graminearum spore germination at 0.5 mg/mL[2].
2-Methoxyjuglone potently inhibits the viability of human colon carcinoma HT-29 cells (IC50 = 2.6 μg/mL) and human breast carcinoma MCF-7 cells (IC50 = 1.2 μg/mL)[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HepG2 human hepatocellular carcinoma cells
-
Concentration:1.6, 3.2, 4.8, 6.4, 8.0 μg/mL
-
Incubation Time:24, 48, 72 h
-
Result:Induced dose-dependent and time-dependent decreases in cell viability.
Reached IC50 values of 3.8 μg/mL (24 h), 3.7 μg/mL (48 h), and 2.7 μg/mL (72 h).
-
Cell Line:HepG2 human hepatocellular carcinoma cells
-
Concentration:4.8, 8.0 μg/mL
-
Incubation Time:24 h
-
Result:Caused cell shrinkage and membrane blebbing at 4.8 μg/mL.
Induced almost all cells to shrink with no normal morphological features at 8.0 μg/mL.\nReduced the number of cells on coverslips significantly and induced nuclear condensation with yellow staining (early apoptosis) at 4.8 μg/mL.
Caused almost all cells to detach from coverslips, with orange staining and apoptotic body formation (late apoptosis) at 8.0 μg/mL.
-
Cell Line:HepG2 human hepatocellular carcinoma cells
-
Concentration:1.6, 3.2, 4.8, 6.4, 8.0 μg/mL
-
Incubation Time:24, 48 h
-
Result:Increased the fraction of cells in the S phase (62%, 64%, 62%, 61%, 59% at 1.6, 3.2, 4.8, 6.4, 8.0 μg/mL, respectively) and decreased fractions in G1 and G2/M phases after 24 h.
Increased the fraction of cells in the S phase (49%, 64%, 66%, 52%, 46% at 1.6, 3.2, 4.8, 6.4, 8.0 μg/mL, respectively) after 48 h.
Induced dramatic increases in sub-G1 phase fraction (18% and 33%, respectively) at 6.4 and 8.0 μg/mL for 48 h, indicating DNA fragmentation associated with apoptosis.
-
Cell Line:HepG2 human hepatocellular carcinoma cells
-
Concentration:1.6, 3.2, 4.8 μg/mL
-
Incubation Time:24 h
-
Result:Increased cytoplasmic cytochrome c levels in a dose-dependent manner.
Activated caspase-9 via proteolytic cleavage of the 47 kDa pro-enzyme to the 35 kDa active form, increasing the cleaved/uncleaved ratio.
Activated caspase-3 via proteolytic cleavage of the 35 kDa pro-enzyme to the 17 kDa active form, increasing the cleaved/uncleaved ratio.
Increased the cleaved/uncleaved PARP ratio.
Elevated pro-apoptotic Bax protein levels and reduced anti-apoptotic Bcl-2 protein levels in a dose-dependent manner, resulting in an elevated Bax/Bcl-2 ratio.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Kunming mice (male, SPF, 6 weeks old, 18-22 g, subcutaneous inoculation of H22 hepatocellular carcinoma cells)[1]
-
Dosage:0.25 mg/kg; 0.5 mg/kg; 1.0 mg/kg
-
Administration:i.p.; daily; 8 days
-
Result:Reduced tumor mass in mice.
Did not reduce the normal weight (total weight minus tumor weight) of mice at any tested dose.
Chemical Information
-
CAS No. 15127-94-3
-
Masse moléculaire 204.18
-
Formule C11H8O4
-
SMILES
O=C1C=C(C(C2=C1C(O)=CC=C2)=O)OC
-
Structure Classification
-
Initial Source
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
[1]. Yu HY, et al. 2-methoxyjuglone induces apoptosis in HepG2 human hepatocellular carcinoma cells and exhibits in vivo antitumor activity in a H22 mouse hepatocellular carcinoma model. J Nat Prod. 2013;76(5):889-895. [Content Brief]
[2]. Yu HY, et al. 2-Methoxyjuglone, a Promising Bioactive Compound for Pharmaceutical and Agricultural Purposes: A Review. Curr Med Sci. 2022;42(5):905-912. [Content Brief]
[3]. Li G, et al. DNA topoisomerases I and II inhibitory activity of constituents isolated from Juglans mandshurica. Arch Pharm Res. 2003;26(6):466-470. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
2-Methoxyjuglone Related Classifications
HY-N17440 Related Classifications
Powered by Bioz